Teflaro 2014 U.S. PROMOTIONAL AUDIT REPORT

Published July 2015 • 31 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Teflaro through personal promotion in 2014 and how does this compare to its peer set in the Community-Acquired Pneumonia, Methicillin-Resistant Staphylococcus Aureus Infection, Severe Infection, and Skin and Soft Tissue Infection markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Forest’s depth of coverage vary within key specialties (e.g., Internal Medicine, Infectious Disease, Emergency Medicine, Pulmonology, Family Medicine, General Surgery, and Critical Care Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Teflaro throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Teflaro in 2014?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 16,900 paid interactions across 7,500 physicians made on behalf of Teflaro were carefully examined to support our analysis. In addition, interaction data from 6 peer products (e.g. Cubicin, Dalvance, Invanz, Sivextro, Vibativ, and Zyvox) was leveraged to provide benchmarking and market insights.